Company Overview and News

 
Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

2018-04-18 globenewswire
WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of Susan Washer to its Board of Directors.
Upvote Downvote

 
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

2018-04-18 globenewswire
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has dosed the first patient in the Company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).
Upvote Downvote

 
AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)

2018-04-10 globenewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the completion of enrollment in a clinical study of the company's gene therapy product candidate, in collaboration with Biogen, for the treatment of x-linked retinoschisis (XLRS).
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp 8-K (Current Report)

2018-03-02 sec.gov
8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp / INTERWEST PARTNERS VIII LP - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
SC 13G/A OMB APPROVAL OMB Number:   3235-0145 Expires:   February 28, 2010 Estimated average burden hours per response   10.4       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO 3)*     Applied Genetic Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 03820J 10 0 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement)     Check the appro
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp / INTERWEST PARTNERS VIII LP - SC 13G/A (Passive Investment)

2018-02-14 sec.gov
SC 13G/A OMB APPROVAL OMB Number:   3235-0145 Expires:   February 28, 2010 Estimated average burden hours per response   10.4       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO 3)*     Applied Genetic Technologies Corp (Name of Issuer) Common Stock (Title of Class of Securities) 03820J 10 0 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement)     Check the appro
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 APPLIED GENETIC TECHNO CORP COMMON STOCK Cusip #03820J100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #03820J100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 800 Item 6: 0 Item 7: 290,530 Item 8: 0 Item 9: 290,530 Item 11: 1.605% Item 12: HC Cusip #03820J100 Item 1: Reporting Person - Abigail P.
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-13 fintel.io
Applied Genetic Technologies Corp (NASDAQ:AGTC) has 82 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 8,012,448 shares. Largest shareholders include Interwest Venture Management Co, Acadian Asset Management Llc, Numeric Investors Llc, Vanguard Group Inc, Ajo, Lp, BlackRock Inc., DAFNA Capital Management LLC, Dimensional Fund Advisors Lp, Renaissance Technologies LLC, and FMR LLC / Fidelity.
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 3 APPLIED GENETIC TECHNO CORP COMMON STOCK Cusip #03820J100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #03820J100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 800 Item 6: 0 Item 7: 290,530 Item 8: 0 Item 9: 290,530 Item 11: 1.605% Item 12: HC Cusip #03820J100 Item 1: Reporting Person - Abigail P.
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp 10-Q (Quarterly Report)

2018-02-09 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 <
Upvote Downvote

1
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2018 Results - Earnings Call Transcript

2018-02-09 seekingalpha
Applied Genetic Technologies Corporation (NASDAQ:AGTC) Q2 2018 Earnings Conference Call February 9, 2018 8:00 AM ET
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp 8-K (Current Report)

2018-02-09 sec.gov
8-K     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2018     APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter)       Delaware   001-36370   59-3553710 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number) 14193 NW 119th
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp DEF 14A

2018-01-29 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934     Filed by the Registrant  ☒                            Filed by a Party other than the Registrant  ☐ Check the appropriate box:   ☐   Preliminary Proxy Statement ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒   Definitive Proxy Statement ☐   Definitive Additiona
Upvote Downvote

 
AGTC / Applied Genetic Technologies Corp 8-K (Current Report)

2017-12-21 sec.gov
8-K     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2017     APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter)       Delaware   001-36370   59-3553710 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number) 14193 NW 119th
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 03820J100